Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: RTN022
MIFTS: 52

Retinal Vein Occlusion

Categories: Cardiovascular diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Retinal Vein Occlusion

About this section

MalaCards integrated aliases for Retinal Vein Occlusion:

Name: Retinal Vein Occlusion 38 12 55 44 15 73
Occlusion, of Retinal Vein 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1727
MeSH 44 D012170
NCIt 50 C34981
SNOMED-CT 68 46085004
UMLS 73 C0035328
Sources

Summaries for Retinal Vein Occlusion

About this section
MalaCards based summary : Retinal Vein Occlusion, also known as occlusion, of retinal vein, is related to macular retinal edema and purpura. An important gene associated with Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and G-protein signaling Ras family GTPases in kinase cascades (scheme). The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are homeostasis/metabolism and cardiovascular system

Sources

Related Diseases for Retinal Vein Occlusion

About this section

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 276)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 31.7 IL6 SERPINF1 VEGFA
2 purpura 30.5 APOH F2 SERPINC1
3 arteritic anterior ischemic optic neuropathy 30.4 F2 F5 MTHFR
4 factor xii deficiency 30.4 APOH F5 SERPINC1
5 thrombocytosis 30.4 F2 IL6 SERPINC1
6 branch retinal artery occlusion 30.3 APOH F2 MTHFR SERPINC1
7 retinal vasculitis 30.3 APOH CCL2
8 nonarteritic anterior ischemic optic neuropathy 30.2 F2 F5 MTHFR SERPINC1
9 central retinal vein occlusion 30.2 APOH F2 F5 IL6 LOXL1 MTHFR
10 microvascular complications of diabetes 5 30.0 SERPINE1 SERPINF1 VEGFA
11 macular holes 30.0 CCL2 SERPINF1 VEGFA
12 retinal vascular disease 30.0 MTHFR SERPINF1 VEGFA
13 ischemic optic neuropathy 29.9 APOH F2 F5 MTHFR SERPINC1
14 protein c deficiency 29.9 F2 F5 MTHFR SERPINC1
15 eclampsia 29.8 F2 F5 MTHFR SERPINC1
16 protein s deficiency 29.8 APOH F2 F5 MTHFR SERPINC1
17 sneddon syndrome 29.7 APOH F2 F5 SERPINC1
18 pulmonary hypertension 29.5 IL6 SERPINC1 SERPINE1 VEGFA
19 temporal arteritis 29.5 APOH CCL2 IL6
20 antithrombin iii deficiency 29.5 APOH F2 F5 MTHFR SERPINC1
21 antiphospholipid syndrome 29.5 APOH F2 F5 MTHFR SERPINC1
22 retinal artery occlusion 29.3 APOH F2 F5 MTHFR SERPINC1 SERPINE1
23 diabetic macular edema 29.3 CCL2 IL6 SERPINF1 VEGFA
24 thrombophilia 29.2 APOH F2 F5 MTHFR SERPINC1 SERPINE1
25 cerebrovascular disease 29.1 F2 F5 IL6 MTHFR SERPINE1
26 thrombosis 28.9 APOH F2 F5 MTHFR SERPINC1 SERPINE1
27 thrombophilia due to thrombin defect 28.7 APOH F2 F5 MTHFR SERPINC1 SERPINE1
28 coronary artery anomaly 28.5 CCL2 F5 IL6 MTHFR SERPINE1
29 hellp syndrome 27.9 APOH F2 F5 IL6 MTHFR SERPINC1
30 arteries, anomalies of 27.4 CCL2 F2 IL6 MTHFR SERPINC1 SERPINE1
31 pre-eclampsia 27.4 APOH F2 F5 IL6 MTHFR SERPINC1
32 retinal vascular occlusion 27.1 APOH CCL2 F2 F5 MTHFR SERPINC1
33 myocardial infarction 26.6 CCL2 F2 F5 IL6 ITGA2 MTHFR
34 vascular disease 26.5 APOH CCL2 F2 F5 IL6 MTHFR
35 partial of retinal vein occlusion 12.2
36 retinitis 11.3
37 paracetamol poisoning 10.8 F2 F5
38 hemifacial spasm 10.8 MTHFR VEGFA
39 mesenteric vascular occlusion 10.8 F2 MTHFR
40 may-thurner syndrome 10.8 APOH F5
41 osteoporotic fracture 10.8 IL6 MTHFR
42 hemoglobin e disease 10.7 F2 F5
43 acanthamoeba keratitis 10.7 APOH F5
44 ischemic neuropathy 10.7 F2 MTHFR
45 critical limb ischemia 10.7 IL6 VEGFA
46 pregnancy loss, recurrent 1 10.7 APOH F5
47 intestinal impaction 10.7 F2 SERPINC1
48 fournier gangrene 10.7 F2 SERPINC1
49 factor viii deficiency 10.7 F2 F5
50 leech infestation 10.7 F2 SERPINC1

Graphical network of the top 20 diseases related to Retinal Vein Occlusion:



Diseases related to Retinal Vein Occlusion
Sources

Symptoms & Phenotypes for Retinal Vein Occlusion

About this section

MGI Mouse Phenotypes related to Retinal Vein Occlusion:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 APOH F2 SERPINE1 F5 VEGFA IL6
2 cardiovascular system MP:0005385 9.97 SERPINC1 F2 SERPINE1 SERPINF1 F5 VEGFA
3 integument MP:0010771 9.76 F2 SERPINE1 F5 VEGFA IL6 ITGA2
4 nervous system MP:0003631 9.61 SERPINC1 F2 SERPINF1 F5 VEGFA IL6
5 reproductive system MP:0005389 9.17 SERPINC1 F2 SERPINF1 VEGFA IL6 LOXL1
Sources

Drugs & Therapeutics for Retinal Vein Occlusion

About this section

Drugs for Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
5
Verteporfin Approved, Investigational Phase 4 129497-78-5
6
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
7
Glucosamine Approved, Investigational, Nutraceutical Phase 4,Not Applicable 3416-24-8 439213
8
Lactitol Investigational Phase 4 585-86-4 3871
9 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
19 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
21 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
32 Fibrinolytic Agents Phase 4,Phase 3,Phase 1,Not Applicable
33 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Dexamethasone 21-phosphate Phase 4
37 Mitomycins Phase 4
38 Anticoagulants Phase 4,Phase 3,Not Applicable
39 Glucuronyl glucosamine glycan sulfate Phase 4,Not Applicable
40 Hypoglycemic Agents Phase 4,Not Applicable
41 Dermatologic Agents Phase 4,Phase 1,Phase 2
42 Photosensitizing Agents Phase 4
43
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
44
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
45
Povidone-iodine Approved Phase 3,Not Applicable 25655-41-8
46
Betamethasone Approved, Vet_approved Phase 2, Phase 3 378-44-9 9782
47
Ephedrine Approved Phase 2, Phase 3 299-42-3 9294
48
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
50
Pseudoephedrine Approved Phase 2, Phase 3 90-82-4 7028

Interventional clinical trials:

(show top 50) (show all 223)
# Name Status NCT ID Phase Drugs
1 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
2 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
3 Retinal Sensitivity in BRVO After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
4 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
5 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
6 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
7 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4 Lucentis
8 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4 ranibizumab
9 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
10 Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4 Avastin;Osurdex;Avastin
11 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
12 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
13 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4 dexamethasone intravitreal implant
14 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
15 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
16 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4 Dexamethasone
17 Dexamethasone-implant for the Treatment of RVO Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
18 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
19 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed NCT02503540 Phase 4 Aflibercept
20 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
21 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
22 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4 intravitreal ranibizumab
23 Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Recruiting NCT02478515 Phase 4 Ranibizumab
24 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Recruiting NCT02521116 Phase 4
25 Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium Recruiting NCT01573572 Phase 4 pegaptanib sodium injection
26 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
27 Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Active, not recruiting NCT01795209 Phase 4 Ranibizumab
28 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Active, not recruiting NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
29 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Active, not recruiting NCT02953938 Phase 4
30 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Active, not recruiting NCT02274259 Phase 4 Aflibercept;Ranibizumab
31 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion Not yet recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
32 Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Not yet recruiting NCT03056079 Phase 4 Intravitreal aflibercept
33 Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab Not yet recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
34 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) Unknown status NCT01635803 Phase 2, Phase 3 Bevacizumab;Ranibizumab
35 Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO) Unknown status NCT01189526 Phase 3 Ranibizumab
36 Atorvastatin for the Treatment of Retinal Vein Occlusion Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
37 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
38 Effect of Avastin in Juxtafoveal Telangiectasias Unknown status NCT00406380 Phase 3 Bevacizumab
39 Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Unknown status NCT02769169 Phase 2, Phase 3 Lucentis® (Raibizumab) double-dose;Lucentis® (Raibizumab) regular-dose
40 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Completed NCT01599650 Phase 3 Ranibizumab
41 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
42 Ozurdex for Retinal Vein Occlusion Study (ORVO Study) Completed NCT01790685 Phase 2, Phase 3 dexamethasone implant
43 Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Completed NCT01377597 Phase 3 ranibizumab
44 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg
45 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
46 Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Completed NCT00970957 Phase 3 Avastin Intravitreal Injection;Sham Avastin Intravitreal Injection
47 Combined Triple Procedure in Retinal Vein Occlusion (RVO) Completed NCT00805064 Phase 3 triamcinolone and bevacizumab
48 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3 ranibizumab
49 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
50 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed NCT00105027 Phase 3 intravitreal triamcinolone injection;intravitreal triamcinolone injection

Search NIH Clinical Center for Retinal Vein Occlusion

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinal Vein Occlusion cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Retinal Vein Occlusion:
Bone marrow-derived hematopoietic stem cells for retinopathy
Embryonic/Adult Cultured Cells Related to Retinal Vein Occlusion:
Bone marrow-derived hematopoietic CD34+ progenitors PMIDs: 22247454
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22247454

Cochrane evidence based reviews: retinal vein occlusion

Sources

Genetic Tests for Retinal Vein Occlusion

About this section
Sources

Anatomical Context for Retinal Vein Occlusion

About this section

MalaCards organs/tissues related to Retinal Vein Occlusion:

41
Eye, Endothelial, Retina, Bone, Myeloid, Monocytes, Testes
Sources

Publications for Retinal Vein Occlusion

About this section

Articles related to Retinal Vein Occlusion:

(show top 50) (show all 1235)
# Title Authors Year
1
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
2
Effects of Dexamethasone Implant on Multifocal Electroretinography in Central Retinal Vein Occlusion. ( 29403585 )
2018
3
YC-1 Inhibits VEGF and Inflammatory Mediators Expression on Experimental Central Retinal Vein Occlusion in Rhesus Monkey. ( 29364731 )
2018
4
Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure. ( 29399095 )
2018
5
Incidence of retinal vein occlusion in open-angle glaucoma: a nationwide, population-based study using the Korean Health Insurance Review and Assessment Database. ( 29360215 )
2018
6
A 5-Year Follow-Up Study of the Treatment of Macular Edema Due to Retinal Vein Occlusion Using Dexamethasone Intravitreal Implants. ( 29708803 )
2018
7
Retinal vein occlusion associated with combined hormonal contraceptive vaginal ring use. ( 29862193 )
2018
8
TOPICAL DORZOLAMIDE-TIMOLOL WITH INTRAVITREOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL VEIN OCCLUSION: A PILOT STUDY. ( 29864044 )
2018
9
USE OF THE ISCHEMIC INDEX ON WIDEFIELD FLUORESCEIN ANGIOGRAPHY TO CHARACTERIZE A CENTRAL RETINAL VEIN OCCLUSION AS ISCHEMIC OR NONISCHEMIC. ( 29474305 )
2018
10
Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema. ( 29804112 )
2018
11
Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion. ( 29376223 )
2018
12
Cardiovascular risk factors in patients with combined central retinal vein occlusion and cilioretinal artery occlusion: Case report. ( 29505511 )
2018
13
Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study. ( 29855153 )
2018
14
Real-Life Clinical Effectiveness of RazumabAr (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study. ( 29945143 )
2018
15
Relationship between Optical Intensity on Optical Coherence Tomography and Retinal Ischemia in Branch Retinal Vein Occlusion. ( 29942024 )
2018
16
Sex-specific age threshold for increased risk of retinal vein occlusion in Koreans. ( 29787945 )
2018
17
Elevated lipocalin-2 level in aqueous humor of patients with central retinal vein occlusion. ( 29572586 )
2018
18
The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario. ( 29785994 )
2018
19
INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial. ( 29624543 )
2018
20
Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes. ( 29339919 )
2018
21
The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion. ( 29550932 )
2018
22
Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. ( 29399708 )
2018
23
Morphological Implications of Vascular Structures Not Visualized on Optical Coherence Tomography Angiography in Retinal Vein Occlusion. ( 29927465 )
2018
24
Sequential Observations of Conversion from Nonischemic to Ischemic Central Retinal Vein Occlusion Using Optical Coherence Tomography Angiography. ( 29850324 )
2018
25
Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. ( 29185099 )
2018
26
Risk of Retinal Vein Occlusion in Patients With End-Stage Renal Disease: A 12-Year, Retrospective, Nationwide Cohort Study in South Korea. ( 29302692 )
2018
27
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. ( 29632703 )
2018
28
Genetic Background of a Recurrent Unusual Combined Form of Retinal Vein Occlusion: A Case Report. ( 29805379 )
2018
29
Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion. ( 29447089 )
2018
30
Peripheral Microvascular Abnormalities Detected by Wide-Field Fluorescein Angiography in Eyes with Branch Retinal Vein Occlusion. ( 29788006 )
2018
31
Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab. ( 29924853 )
2018
32
Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant. ( 29891733 )
2018
33
Changes in Retinal Microvasculature and Visual Acuity After Antivascular Endothelial Growth Factor Therapy in Retinal Vein Occlusion. ( 29860457 )
2018
34
Correlation between ischemic index of retinal vein occlusion and oxygen saturation in retinal vessels. ( 29366614 )
2018
35
Swept-Source OCT Angiographic Imaging of a Central Retinal Vein Occlusion During Pregnancy. ( 29554389 )
2018
36
Anomalous coagulation factors in non-arteritic anterior ischemic optic neuropathy with central retinal vein occlusion: A case report. ( 29642215 )
2018
37
Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. ( 29855706 )
2018
38
Correlation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusion. ( 29487816 )
2018
39
Impact of Early Anatomical and Functional Responses to Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion. ( 29393235 )
2018
40
Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab. ( 29426292 )
2018
41
Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion. ( 29971447 )
2018
42
Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series. ( 28031700 )
2017
43
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study. ( 28744657 )
2017
44
Central Retinal Vein Occlusion-like Appearance: A Precursor Stage in Evolution of Frosted Branch Angiitis. ( 29090058 )
2017
45
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. ( 28492910 )
2017
46
Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice. ( 28950262 )
2017
47
Unilateral Adult Xanthogranulomatous Infiltration of the Conjunctiva, Limbus and Sclera Leading to a Combined Ophthalmic Artery and Central Retinal Vein Occlusion. ( 29299083 )
2017
48
Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa. ( 28828184 )
2017
49
Author's reply to comments to: Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal. ( 28862735 )
2017
50
BRANCH RETINAL VEIN OCCLUSION SECONDARY TO A RETINAL ARTERIOLAR MACROANEURYSM: A NOVEL MECHANISM SUPPORTED BY MULTIMODAL IMAGING. ( 28079651 )
2017
Sources

Variations for Retinal Vein Occlusion

About this section
Sources

Expression for Retinal Vein Occlusion

About this section
Search GEO for disease gene expression data for Retinal Vein Occlusion.
Sources

Pathways for Retinal Vein Occlusion

About this section

Pathways related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 12.88 APOH F2 F5 ITGA2 SERPINC1 SERPINE1
2
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 11.93 CCL2 SERPINE1 VEGFA
3
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.82 F2 F5 SERPINC1 SERPINE1
4
Interleukin-4 and 13 signaling 66
11.67 CCL2 IL6 VEGFA
5
Complement and coagulation cascades 1 37
11.6 F2 F5 SERPINC1 SERPINE1
6
HIF-1 signaling pathway 37
11.58 IL6 SERPINE1 VEGFA
7
Rheumatoid arthritis 37
11.5 CCL2 IL6 VEGFA
8
Folate Metabolism 1
Show member pathways
 11.35 CCL2 F2 IL6 MTHFR SERPINE1
9
AGE-RAGE signaling pathway in diabetic complications 37
11.25 CCL2 IL6 SERPINE1 VEGFA
10
Glypican 1 network 1
10.94 SERPINC1 VEGFA
11
IL1 and megakaryocytes in obesity 1
10.91 CCL2 F2
12
Immune response_Oncostatin M signaling via JAK-Stat in human cells 22
10.76 CCL2 VEGFA
13
Warfarin Pathway, Pharmacodynamics 61
10.63 F2 VKORC1
Sources

GO Terms for Retinal Vein Occlusion

About this section

Cellular components related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 APOH CCL2 F2 F5 IL6 LOXL1
2 endoplasmic reticulum lumen GO:0005788 9.62 F2 F5 IL6 SERPINC1
3 extracellular matrix GO:0031012 9.56 APOH LOXL1 SERPINE1 SERPINF1
4 platelet alpha granule lumen GO:0031093 9.33 F5 SERPINE1 VEGFA
5 extracellular space GO:0005615 9.32 APOH CCL2 F2 F5 IL6 LOXL1

Biological processes related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.77 ITGA2 MTHFR VEGFA
2 regulation of signaling receptor activity GO:0010469 9.77 CCL2 F2 IL6 SERPINE1 VEGFA
3 regulation of cell shape GO:0008360 9.75 CCL2 F2 VEGFA
4 cellular protein metabolic process GO:0044267 9.73 F2 F5 IL6 SERPINC1
5 cellular response to lipopolysaccharide GO:0071222 9.72 CCL2 IL6 SERPINE1
6 negative regulation of endopeptidase activity GO:0010951 9.7 SERPINC1 SERPINE1 SERPINF1
7 platelet degranulation GO:0002576 9.62 APOH F5 SERPINE1 VEGFA
8 positive regulation of collagen biosynthetic process GO:0032967 9.59 F2 ITGA2
9 positive regulation of JAK-STAT cascade GO:0046427 9.58 F2 IL6
10 hemostasis GO:0007599 9.58 F2 F5 SERPINC1
11 negative regulation of endothelial cell migration GO:0010596 9.57 APOH SERPINF1
12 fibrinolysis GO:0042730 9.56 F2 SERPINE1
13 blood coagulation, intrinsic pathway GO:0007597 9.54 APOH F2
14 negative regulation of blood coagulation GO:0030195 9.51 APOH SERPINE1
15 positive regulation of leukocyte migration GO:0002687 9.49 ITGA2 VEGFA
16 positive regulation of positive chemotaxis GO:0050927 9.48 ITGA2 VEGFA
17 peptidyl-glutamic acid carboxylation GO:0017187 9.46 F2 VKORC1
18 positive regulation of blood coagulation GO:0030194 9.43 APOH F2 SERPINE1
19 blood coagulation GO:0007596 9.35 F2 F5 ITGA2 SERPINC1 VKORC1
20 regulation of blood coagulation GO:0030193 9.33 APOH F2 SERPINC1
21 negative regulation of fibrinolysis GO:0051918 8.8 APOH F2 SERPINE1

Molecular functions related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 F2 IL6 VEGFA
2 serine-type endopeptidase inhibitor activity GO:0004867 9.13 SERPINC1 SERPINE1 SERPINF1
3 heparin binding GO:0008201 8.92 APOH F2 SERPINC1 VEGFA
Sources

Sources for Retinal Vein Occlusion

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....